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Decreased total and active urinary kallikrein in normotensive
Dahi salt susceptible rats
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Stony Brook, New York, USA
Decreased total and active urinary kallikrein in normotensive Dahl salt
susceptible rats. Abnormalities in the kallikrein-kinin system have been
found in human and animal models of essential hypertension. The
purpose of this study is to assess the kallikrein-kinin system in
normotensive Dahl salt sensitive (S) and salt resistant (R) rats on a zero
sodium diet. Urinary kallikrein was measured at 7 and 12 wk of age by
different techniques. When kallikrein activity was assessed, by a
kininogenase assay, S rats excreted 66% (P < 0.001) and 75% (P <0.01)
as much kallikrein as R rats at 7 and 12 wk of age. Using an artificial
substrate method (Kabi S-2266), S rats excreted 30% (P < 0.001) and
56% (P < 0.05) as much kallikrein as R rats at 7 and 12 weeks,
respectively. Using a technique to measure total kallikrein, S rats
excreted 53% (P < 0.001) and 65% (P < 0.05) as much kallikrein as R
rats at 7 and 12 wk of age. Normotensive S rats failed to increase
maximally kallikrein activity or total kallikrein when the diet was
switched from a .4% to a .0064% sodium chloride diet. There was no
difference in inhibitors, as measured by the recovery of purified
kallikrein added to S and R urine (56 21% vs. 53 13%). Km values
for S and R urinary kallikrein were similar (3.1 .5 x l0 vs. 2.6 .5
x i0 M/liter). Trypsin-activatable kallikrein was equivalent in the S
and R rats on the .0064% and .4% sodium chloride diet. This study
supports the hypothesis that there is diminished kallikrein activity in S
rats, and that this is due to decreased kallikein excretion rather than
inhibitors in the urine, an abnormality in the enzyme, or an inactive
enzyme.
Diminution de Ia kallikréine unnaire totale et active chez des rats DahI
normotendus sensibles au sel. Des anomalies du systéme kallikréine.
kinine ont été trouvées dans des modèles humains et animaux
d'hypertension essentielle. Le but de cette étude est de mesurer le
système kallikréine-kinine chez des rats DahI normotendus sensibles au
sel (S) et résistants au sel (R), a un régime sans sodium. La kallikréine
urinaire a été mesurée a 7 et 12 semains d'âge par différentes tech-
niques. Lorsque l'activité kallikréine Ctait measuée par un dosage a Ia
kininogènase, les rats S excrétaient 66% (P < 0,001) et 75% (P < 0,01)
de la kallikréine de rats R âgés de 7 a 12 semaines, respectivement. En
utilisant une méthode avec un substrat artificiel (Kabi S-2266), les rats
S excrétaient 30% (P < 0,001) et 56% (P < 0,05) de Ia kallikréine de rats
R âgés de 7 et 12 semaines, respectivement. En utilisant une technique
mesurant Ia kallikréine totale les rats S excrétaient 53% (P < 0,001) et
65% (P < 0,05) de kallikréine de moms que les rats ages de septet douze
semaines. Les rats S normotendus ont été incapable d'élever au
maximum leur activité kallikréine et leur kallikréine totale lorsque le
régime était change d'un régime a 0,4% pour un régime a 0,0064% de
chlorure de sodium. Ii n'existait pas de difference dans les inhibiteurs
mesurés par Ia récupération de kallikréine purifiée ajoutée a des urines
S et R (56 21% contre 53 13%). Les valeurs de Km de Ia kallikrCine
urinaire S et R étaient semblables (3,1 0,5 >< lO M/liter). La
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kallikréine trypsine-activable était equivalente chez les rats S et R aux
regimes a 0,0064% et 0,4% de chlorure de sodium. Cette étude est en
faveur de l'hypothese qu'iI existe une activité kallikréine abaissée chez
les rats S. et que cela est dO a une diminution de l'excrétion de
kallikréine plus qu'à des inhibiteurs urinaires, a une anomalie de
l'enzyme, oil a une enzyme inactive.
Through selective inbreeding, Dahl and his colleagues devel-
oped two strains of Sprague-Dawley rats, one that is sensitive
(S) and one that is resistant (R) to salt-induced hypertension
[1—31. Because of the similarity between this model and human
essential hypertension, many investigators have used it to
examine the factors that are important in the pathogenesis of
hypertension. Work with parabiotic rats suggests that a
hypertensionogenic factor may exist in S rats [4, 5].The nature
of this substance is not known [61. Cross strain transplantation
studies suggest that there is an antihypertensive factor in R
kidneys that protects against the hypertension [7—9]. One potent
vasodilator system that could be the protector is the kallikrein-
kinin system. Kallikrein cleaves kinin from its inactive precur-
sor, kininogen [10]. Kinins promote vasodilation, diuresis, and
natriuresis [10]. Using a TAME esterase assay, one group
reported initially decreased levels of kallikrein esterase activity
[11] in Dahi S rats. In more recent publications, the same group
found that normotensive S rats excrete urinary kallikrein activ-
ity at the same rate as R rats [12, 131. When S rats become
hypertensive, the excretion of kallikrein activity diminishes.
These workers have shown also that hypertension results in
proteinuria, which increases the excretion of specific inhibitory
proteins in S rats that decreases kallikrein activity [14]. Using
specific assays for kallikrein, Carretero et al found decreased
total and active kallikrein in normotensive S rats [15]. The
decrease in kallikrein activity was far greater than the decrease
in total kallikrein. This finding suggests that kallikrein in S rats
may be inhibited, abnormal, or inactive.
The goal of this study was to re-examine the renal kallikrein-
kinin system in Dahi S and R rats. Kallikrein activity of
normotensive S and R rats was measured using a kininogenase
assay [16] and artificial substrate assay [17]. Total kallikrein
immunoreactivity was measured by a radioimmunoassay that
measures both active and inactive kallikrein [18].
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Methods
Protocols
Male Dahl salt sensitive (S) rats and salt resistant (R) rats
were used in this study. These rats were a gift of Dr. Richard
Friedman, Department of Psychiatry, State University of New
York at Stony Brook Health Sciences Center. This colony is a
derivative of the Brookhaven strain inbred by Rapp and his
colleagues. These rats were studied at 7 and 12 wk of age.
Additional S and R rats 7 and 12 wk of age were used for the
studies involving the activation, recovery, and enzyme kinetics
of kallikrein. During urine collections, the rats were housed in
Nalgene metabolic cages, which effectively separated the solid
waste from the urine. Rats were raised on a .4% sodium diet.
Five days prior to the collections, the rats were placed on a
sodium-deficient diet (ICN Nutritional Biochemicals, Cleve-
land, Ohio, USA) containing .0064% sodium. After a five-day
period of acclimation and equilibration to the metabolic cages,
two 24-hr urine samples were collected, In another group of
7-wk old S and R rats, two 24-hr urines were collected after
eating a .4% NaCI diet for five days and after eating a .0064%
NaC1 diet for five days. Urine was collected into containers
containing EDTA and 1,10- phenanthroline at a final concen-
tration of 30 mrvi and 3 m, respectively. At all times, the urine
was chilled in an ice bath to retard the formation of bacteria.
Results are expressed as the average of the two days of
collection.
Analyses
Kallikrein activity levels were determined by the kinino-
genase method and by a colorimetric assay.
Kininogenase assay
All vials and test tubes used were coated with a siliconizing
agent to prevent the adherence of bradykinin on container
walls. A ten-microliter aliquot of urine was added to 490
microliters of partially purified bovine kininogen [191 (2 mg/mI)
diluted in kininogenase buffer (30 m'vi EDTA and 3 mM 1,10-
phenanthroline in .01 M sodium phosphate buffer, pH 8.5)
warmed to 37°C. Simultaneous controls for endogenous urine
kinin levels were measured. Samples were incubated for 20 mm
at 37°C. This assay is done under conditions of substrate excess
and only .1 to .4% of substrate is consumed. Kinin production
was stopped by heat inactivation for 15 mm at 98°C. Samples
were centrifuged at 2500 rpm for 10 mm, and generated kinins
were measured in the supernatant. Kininogenase activity is
reported as micrograms of kinins generated in 20 mm incubation
per day.
Anti-bradykinin antisera was prepared in New Zealand white
rabbits. Bradykinin triacetate (Sigma Chemical Company, St.
Louis, Missouri, USA) was coupled to bovine serum albumin
by the carbodiimide method [201. The conjugated bradykinin (2
mg in complete Freund's adjuvant) was administered monthly.
The rabbit was bled 33 wk after the initial immunization.
The kinins were measured by radioimmunoassay similar to
the one developed by Shimamoto et al [21]. One hundred
microliters of RIA buffer (.01 MPBS,pH = 7.0, .14MNaCI, .01
M EDTA and .003 M 1 ,10-phenanthroline with 1% ovalalbumin),
tracer (V25-bradykinin, NEN diluted to 5000 cpm per tube with
RIA buffer), antisera (1/500 dilution in RIA buffer) and standard
or sample were mixed, precounted, and incubated at 4°C for 18
hr.
A standard curve was prepared with bradykinin ranging from
0 pg to 1000 pg per tube. The degree of non-specific binding was
determined by including duplicate tubes with 100 microliters of
non-immune serum diluted 1:500. Solutions were pipetted into
tubes using a micromedic automatic pipettor dilutor. The reac-
tion was stopped by adding 500 microliters of ice cold 25% PEG
in PBS and 100 microliters of 1% bovine gamma-globulins in
PBS. The tubes were vortexed and then centrifuged for 20 mm
at 4000 rpm at 4°C. The supernatant was poured off, the tubes
were wiped dry, and the radioactivity bound in the precipitate
was counted.
Artificial substrate assay for kallikrein activity
A colorimetric method was also employed to measure kal-
likrein activity also [17]. An artificial substrate S-2266 (Kabi
Diagnostics, Stockholm, Sweden), whose structure is H-D-Val-
Leu-Arg-pNa, was used. This assay is based upon kallikrein's
ability to cleave amide bonds and release paranitroanilide. A
20-microliter urine sample was added to 880 microliters of .2 M
tris-HC1 buffer (pH = 8.2 at 25°C) and then thermostated to
37°C in a cuvette. When this solution was equilibrated, 100
microliters of S-2266 (2.5 m in distilled water at 37°C), was
added. The change in absorbence was read against a distilled
water blank at 405 nm for 5 mm in a Beckman spectrophotom-
eter. The slope of the line generated in moles of paranitroanilide
per minute was used as the activity measurement. The produc-
tion of paraanitroanilide was linear throughout the assay and
less than 5% of the substrate was consumed.
Direct assay for total kallikrein
Total kallikrein was measured by the direct immunoassay
similar to that of Shimamoto et al [18]. This assay measures
total kallikrein, active and inactive. This is based on previous
unpublished findings that trypsin activation increases urinary
kallikrein activity (Sprague-Dawley rats on a .4% NaC1 diet)
(320 100 to 450 170 pg BK generated per 10 microliter
urine, P < 0.05) and aprotinin treatment decreases activity from
(320 100 to 0 pg BK generated per 10 microliter urine, P <
0.05), while total kallikrein does not change (900 220 to 810
260 to 930 200 pg per 10 microliter of urine, P > 0.05). Thus,
activity can be increased or decreased without changing total
immunogenic kallikrein. Sheep anti-rat urinary kallikrein was
derived from kallikrein purified by affinity chromatography on a
trasylol sepharose column [22]. The kallikrein was purified
further by polyacrylamide disc gel electrophoresis, and the
kallikrein peak was cut from the gel and used as immunogen.
The immunogen was mixed with complete Freund's adjuvant
and injected into a sheep, followed by monthly booster injec-
tions. Antibody was harvested at 6 months post-initial immuni-
zation. Purified kallikrein was iodinated by the chloramine T
procedure [18, 23].
Total kallikrein was measured by RIA. Each sample and
standard was measured in duplicate. One hundred microliters of
assay buffer (.14 M NaCI in .01 M PBS, pH = 7 with 1% bovine
serum albumin), tracer (10,000 cpm per tube), antisera (1/30,000
dilution in .05 M EDTA in PBS with .5% non-immune sheep
serum), and standard or sample were mixed in biovials. A
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standard curve ranging from 0 pg to 10,000pg of kallikrein per
tube was used. Samples were incubated for 18 hours at 4°C. The
reaction was stopped by adding 800 microliter 25% PBS and 400
microliter 1% bovine IgG in PBS. The tubes were centrifuged at
4000 rpm at 4°C for 30 mm. The supernatants were decanted,
and the tubes were wiped. Bound counts were measured in the
gamma counter.
Activation and recovery studies
Samples were treated with trypsin to assess the amount of
inactive kallikrein present. A 100-microliter aliquot of urine was
incubated with 15 /11 of trypsin bound to sepharose gel beads
[24, 251 and 85 pA of distilled water for 1 hr at 37°C. A second
sample of 100 microliters of urine and 100 microliters of distilled
water was incubated similarly. A third control tube was pre-
pared in the same manner with 15 microliters of trypsin and 185
microliters of distilled water. After incubation the samples were
centrifuged immediately for 5 mm at 2500 rpm, and liquid
supernatant was separated from the gel. Kininogenase activity
was measured in all tubes. Inactive kallikrein would be equal to
the increase in kininogenase activity secondary to the trypsin
activation.
Percentage recovery was found by adding kallikrein to urine
samples and determining the recovery of kallikrein activity in
urine compared to kallikrein activity in distilled water. For each
urine sample (N = 26), three samples were prepared in dupli-
cate consisting of 100 microliters urine plus 100 microliters of
distilled water, 100 microliters urine plus 100 microliters of
kallikrein, and 100 microliters of kallikrein plus 100 microliters
of distilled water. Kallikrein activity was measured by a
kininogenase assay. The percentage recovery of purified kal-
likrein in urine was calculated.
Enzyme kinetic studies
Enzyme kinetic studies were performed using S-2266 (Kabi)
as the artificial substrate for kallikrein. Rates of reaction were
measured at 37°C using the protocol detailed previously to
measure kallikrein activity. Measurement of reaction rates were
made at .05, .1, .15, .20, and .25 m substrate concentrations.
Linearity was ensured by recording the rate of liberation of
paranitroanilide from the substrate. The .05 m substrate
concentration was linear for the first 3 mm. Between 4 and 5
mm the rate of reaction plateaued. Km values were calculated
using a Lineweaver-Burke transformation.
DEAE kallikrein recovery studies
To replicate the work of Sustarsic, McPartland, and Rapp
[12], six urine samples were dialyzed and placed on minicolumn
containing DEAE A-SO to separate kallikrein from esterase A2.
Prior to the separation, 1 ml of each sample was dialyzed at 4°C
against distilled water for 24 hr. The water was replaced with
500 ml of chromatography buffer (.01 M potassium phosphate,
pH = 7), and the samples were dialyzed for 48 hr at 4°C with a
fresh buffer change at 24 hr. A 50-microliter aliquot of dialyzed
sample was set aside for later analysis.
Six siliconized 5 3/4" disposable Pasteur pipets with bed
volumes of 2 ml were used as columns. DEAE-Sephadex A-SO
(Pharmacia, Uppsala, Sweden) was swelled in chromatography
buffer (.1 M KBS, pH = 7) for 24 hr at room temperature. The
columns were packed and equilibrated with a solution of .2 M
KC1 in chromatography buffer. To each sample, KC1 was added
to a final concentration of .2 M so that its ionic strength was
equal to that of the equilibrating buffer. Samples were applied to
the columns which were then washed with 5 column volumes
(10 ml) of equilibrating solution to remove the non-kallikrein
esterase. The absorbed kallikrein was eluted with a wash of .7
M KC1 in chromatography buffer. The first .5 ml of the column
was discarded, and the next 3.5 ml was collected as a single
fraction. Direct kallikrein and kininogenase assays were per-
formed on a the 50-microliter dialyzed aliquot and on the 3.5 ml
sample collected from the column.
The protein content of the urine was analyzed using the
Lowry method [26]. Sodium and potassium levels were mea-
sured by flame photometry using a Beckman KLINA flame
photometer. Blood pressures were measured with a tail cuff
manometer [271.
Statistics
Dahl S and R rats of the same age were compared by a
non-paired t test. The same rats studied at different ages or on
different diets were compared by paired t tests. A correlation
between two variables such as kininogenase assay and artificial
substrate assay methods was done by least square linear
regression analysis. A significant correlation is defined by the
slope being significantly different than zero.
Results
All animals were in sodium and potassium balance during the
two days of collection on either the .0064% or the .4% NaCI
diet. On the .4% NaC1 diet, mean systolic blood pressures were
as follows: 120 3 mm Hg for 7-wk R rats, 124 2 mm Hg for
7-wk S rats, 124 1 mm Hg for 12-wk R rats, and 151 6mm
Hg for 12-wk S rats. There was no difference in blood pressures
between S and R rats at 7 wk, but 12-wk S rats had significantly
increased blood pressures, despite eating a sodium-restricted
.4% NaC1 diet.
The excretion of active kallikrein measured by the
kininogenase assay method is depicted in Figure 1A. The
activity is expressed in micrograms of kinin generated in 20 mm
per day. At 7 wk, kallikrein activity of the R rats was 13.0 .7,
compared to 8.6 .5 for the S rats (P < 0.001). At 12 wk,
kallikrein activity for the R rats was 13.4 .8, compared to 10.1
.5 for the S rats (P < 0.05). Kininogenase activity did not
change with age in R rats (P > 0.5), but tended to increase in the
S rats (P < 0.01).
The excretion of active kallikrein measured by the artificial
substrate method (Fig. 1B) is expressed in millimoles of pNa
cleaved per day. At 7 wk, kallikrein activity of the R rats was
63.1 2.5 compared to 23.0 .7 for the S rats (P < 0.001). At
12 wk, kallikrein activity for the R rats was 65.5 9.0,
compared to 36.8 1.9 for the S rats (P < 0.05). In the R rats,
there was no increase in activity with age. Activity increased
significantly with age in S rats (P < 0.001). When the
kininogenase activity of each sample is plotted against kal-
likrein activity measured by the artificial substrate method,
there is a significant correlation, as described by the line y = .1
x + 6.7 (r =
.78) (P < 0.001) (Fig. 2). The line appears not to
go through the origin. Since there are no kininogenase values
less than 6 and no artificial substrate values less than 16, we
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Fig. 1. Kallikrein activity measured by the kininogenase (A) and an
artificial substrate (Kabi-S-2266) assay (B) in Dahi R rats and Dahi
S rats — at 7 and 12 wk of age on .0064% NaCI diet. 5p < 0.001 bp
<0.05,
cannot evaluate statistically whether the intercept is different
from zero.
In a separate group of 7-wk rats (N 5) kallikrein was
measured in both the S and R rats when the rats were switched
from a low-salt .4% NaCI diet to a no-salt .0064% NaC1 diet
(Fig. 3 and Table 1). The increase in kininogenase activity was
greaterinRrats(7.1 .3 to 12.1 .4)thantheSrats(5.4± .3
to 7.2 .2). Immunoreactive kallikrein increased in the R rats
(17.8 1.9 to 36.1 2.6), but did not change in the S rats (16.5
1.3 to 15.9 1.5). The dietary-stimulated S kallikrein activity
(.0064% NaC1 diet) was equal to the suppressed activity (.4%
NaC1 diet) of the R rats, suggesting an inability of S rats to
respond to normal kallikrein activity.
Total immunoreactive kallikrein was significantly higher in R
rats (Fig. 4). As 7-wk total kallikrein excretion was 52.8 2.7
gIday for the R strain and 28.0 2.4 gIday for the S strain (P
< 0.001). At 12 wk, total kallikrein excretion was 41.7 3.3
gIday for the R rats and 27.1 3.5 jig/day for the S rats (P <
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Fig. 2. Relationship of kininogenase and artificial substrate methods to
measure kallikrein activity. Symbols are: , S rats; 0, R rats. Signifi-







Fig. 3. Kininogenase activity on .4% and .0064% NaC1 diets. Symbols
are: S rats; 0—0, R rats.
with age in the R rats (P < 0.05) but did not change in the S rats
(P> 0.5).
















.4% NaCI diet 7.1 .3 17.8 1.9 .41 .03
.0064% NaCI diet 12.1 4" 36.1 26b .36 .03
DahI S rat
.4% NaCI diet 5.4 .3 16.5 1.3 .37 .03
.0064% NaCI diet 7.2 .2 15.9 1.5 .46 .03
a p < 0.05
b P < 0.001
7wk l2wk
Fig. 4. Excretion of total kallikrein measured by RIA of DahI R El and
DahI S — rats at 7 and 12 wk of age. P < o,o5, bp < 0.001.
of kallikrein activity per milligram of kallikrein. The ratio of
kininogenase activity to total kallikrein (immunoreactive) at 7
wk was .25 .09 for the R rats and .31 .03 for the S rats (P
<0.01). At 12 wk, this ratio was .33 .02 for the R rats and .41
.06 for the S rats (P > 0.2).
Protein excretion was lower in the R rats than in the S rats. At
7 wk, urinary protein levels were 2.4 .4 mg/day for the R rats
and 14.5 1.4 mg/day for the S rats (P < 0.001). At 12 wk,
protein excretion was 9.8 .6 mg/day for the R rats and 51.6
4.0 mg/day for the S rats (P < 0.001), Protein excretion
increased with age in both strains (P < 0.00 1). There was no
significant correlation between protein excretion and kallikrein
activity, AfT ratio, or recovery of purified kallikrein within a
strain.
Trypsinization of urines from S and R rats results in increased
kininogenase activity. Eight urines from S and R rats eating a
.4% NaCI diet increased kininogenase activity from 527 47
ng/ml to 643 38 ng/ml (P <0.05), and ten urines from R rats
eating a .0064% NaCI diet increased kininogenase activity from
705 83 to 906 74 ng/ml (P < 0.05). Eight urines from S rats
eating a .4% NaC1 diet increased from 443 43 to 641 71
ng/ml (P < 0.01), and ten urines from S rats eating a .0064%
NaCI diet increased from 376 43 to 559 80 ng/ml (P < 0.05).
There was no statistical difference between the absolute amount
of activatable kallikrein present or the percentage activation in
S and R urines on any diet.
The percentage recovery of purified kallikrein activity was
the same for the two strains, 56 21% for the S rats (N = 13)
and 53 13% for the R rats (N 13) (P > 0.5).
The Km, affinity constant calculated for kallikrein using a
Lineweaver-Burke transformation was 3.1 .5 X iO M/liter
for S animals and 2.6 .5 X i0 M/liter for R animals (P >
0.5).
Total and active kallikrein was measured in six urine samples
(three S and three R) before and after ion exchange chromatog-
raphy to remove esterase A2. There was no change in the
kininogenase activity before or after the column (15.3 1.0 vs.
15.1 2.0 g of bradykinin generated in 20 mm/day). Im-
munoreactive kallikrein decreased by 75% (10.1 1.1 vs. 2.5
.3 jig/day.
Discussion
Dahi salt-sensitive rats have a genetic predisposition to
develop hypertension. The aim of this study was to evaluate
whether they have a hereditary defect in the renal kallikrein-
kinin system. To accomplish this, Dahl S and R rats were
studied at 7 wk of age, when they were clearly normotensive.
They were studied again at 12 wk of age when the S rats blood
pressure had risen moderately. In both cases, the excretion of
active and total kallikrein measured by different assays was
lower in S rats. Based on this data, we conclude that the
decrease in urinary kallikrein seen in S rats is an inherited
defect and not a result of the hypertension.
To test whether the decrease in kallikrein was due to an
inactive, inhibited, or an abnormal enzyme, we examined the
amount of inactive kallikrein present (trypsin activation), the
level of urinary kallikrein inhibitors (kallikrein recovery), and
the integrity of the enzyme (Km, affinity constant). The per-
centage of inactive kallikrein activated by trypsin was not
different between the S and R rats eating either a .0064% or a
.4% NaCl diet. Thus, it is unlikely that the decrease in kallikrein
activity is due to an increased amount of inactive kallikrein.
There was no difference in the recovery of purified kallikrein;
approximately half the added kallikrein was inhibited by spe-
cific and non-specific inhibitors in S and R urines. Thus, it is
unlikely that kallikrein inhibitors alone are responsible for the
difference in kallikrein activity between S and R rats. Finally,
the affinity constant, Km, of kallikrein was not different in S and
R rat urines. Thus, a functionally abnormal enzyme is not a
likely cause of the decreased kallikrein activity in S rats. Based
on this data, we conclude that the decrease in kallikrein
Table 1. Effect of low-salt diet (.4% NaCI) and no-salt diet (.0064%
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excretion in normotensive S rats is not due to an inactive,
inhibited, or abnormal enzyme. Using the method of Miller,
Lindley, and Margolius, future studies will need to address
whether the decrease in kallikrein excretion is due to a decrease
in synthesis of kallikrein [281.
It has been reported that R rats do not suppress urinary
kallikrein excretion when dietary sodium [29] is increased. We
found that both S and R rats increased kallikrein activity
(kininogenase assay) upon switching to a .0064% NaCI diet. The
percentage increase in kallikrein activity in R animals (70%)
was significantly greater than S animals (33%) (Fig. 3 and Table
1). In fact, the dietary-stimulated kininogenase activity in S
animals was only equal to the non-stimulated kininogenase
activity in R animals. Immunoreactive kallikrein increased in
the R animals by 103%, but did not increase in S animals (—4%).
This experiment demonstrates that S animals cannot respond to
dietary stimuli, which in normal animals and people increases
immunoreactive kallikrein [30].
One could hypothesize that the failure to stimulate kallikrein
under normal physiologic conditions may be related to the
pathogenesis of the hypertension. For example, if the renal and
peripheral vascular resistance is dependent on the dilatory
capacity of the kallikrein-kinin system, then either abnormal
regulation or a deficiency in the system could account for
increased vascular resistance and resultant hypertension. This
type of speculation has been used previously in the reports of
decreased kallikrein excretion in human essential hypertension.
Further crossbreeding studies are needed to determine whether
the defect in kallikrein excretion or abnormal regulation paral-
lels the salt-sensitive hypertension. This would help define
whether abnormalities in the kallikrein-kinin system are impor-
tant in the pathogenesis of the hypertension.
Previously, Sustarsic, McPartland, and Rapp found that
kallikrein activity is unchanged in normotensive S rats [12,
131—a result that differs dramatically from the present study.
Several possibilities could account for this difference. In previ-
ous studies, rats were raised on a 1% NaCI diet. The
normotensive animals in this study were bred on a .4% NaC1
diet and studied under dietary stimulation on a .0064% NaCl
diet. The difference in kallikrein excretion between strains
might have been suppressed by the 1% NaCI diet. In fact, the
difference between S and R rats on .4% NaCI diet is arithmet-
ically less significant (Fig. 3). Another difference between the
two studies is the methods employed to measure kallikrein.
Previous studies used a TAME esterase assay to measure
kallikrein activity. The esterase assay is not specific for kal-
likrein activity [31] and a separation technique, anion exchange,
must be employed to remove esterase A2 from kallikrein. We
found that when this separation technique was applied to a
group of samples from this study, an average of 75% of the
immunogenic kallikrein remained on the column following
elution. Kallikrein activity was equivalent before and after the
chromatographic separation, probably as a result of the removal
of kallikrein inhibitors or activation of inactive kallikrein.
It has been suggested that the diminished kallikrein observed
in hypertensive S rats is related to their development of
proteinuria as they become progressively hypertensive. We
found no correlation between protein excretion and kallikrein
activity in the S and R rats. The lack of a significant correlation
between proteinuria and kallikrein may be due to the fact that
specific kallikrein-binding proteins were not measured.
Carretero et al found that in normotensive S rats, total and
active kallikrein are reduced compared to R controls [15].
Quantitatively, in their study, active kallikrein was reduced to a
greater degree than total. It is possible that this may be a
property of the particular kininogen used in their assay. With
either the bovine kininogen or the artificial substrate we did not
see the same phenomenon.
Finally, we have shown a high degree of correlation between
the kininogenase assay and the artificial substrate assay. De-
spite the lack of data around the origin, we conclude that the
artificial substrate assay is a good tool with which to estimate
kallikrein activity; it is quick, and it has a high degree of
correlation with the kininogenase assay and kallikrein excretion
rates seen under physiological conditions.
In summary, Dahl S rats excrete significantly less kallikrein
enzyme when they are normotensive. Furthermore, S rats do
not increase their kallikrein excretion rate as much as R rats
when they are stimulated by a low-salt diet. The role of this
defect in kallikrein in the pathogenesis of hypertension needs
further examination.
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